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Abstract
It has been a decade since the introduction of SH2 profiling, a modular domain-based molecular diagnostics tool. This review covers the original 
concept of SH2 profiling, different analytical platforms, and their applications, from the detailed analysis of single proteins to broad screening in 
translational research. Illustrated by practical examples, we discuss the uniqueness and advantages of the approach as well as its limitations and 
challenges. We provide guidance for basic researchers and oncologists who may consider SH2 profiling in their respective cancer research, especially 
for those focusing on tyrosine phosphoproteomics. SH2 profiling can serve as an alternative phosphoproteomics tool to dissect aberrant tyrosine 
kinase pathways responsible for individual malignancies, with the goal of facilitating personalized diagnostics for the treatment of cancer.
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Tyrosine Phosphoproteomics in 
Cancer
The availability of $1,000 whole-genome 
sequencing will soon fuel personalized 
medicine for life-threatening human dis-
eases such as cancer.1,2 It is widely 
accepted that somatic gene alteration is 
the primary determinant of cancer and 
can serve as a predictive marker for drug 
response and patient prognosis.3,4 Pro-
teomics, the large-scale analysis of gene 
products, has also caught the attention of 
cancer researchers, with sensitive mass 
spectrometry as the driving force for 
large-scale protein profiling of tumors.5,6 
To design an effective therapy tailored for 
each cancer patient based on gene and 
protein profiles, it is necessary to define 
the critical proteins responsible for the 
hallmarks of cancer, such as oncogenic 
cell growth or resistance to apoptosis.7 
An important goal of current research is 
to exploit these proteins as targets for the 
rational design of highly specific antican-
cer agents. However, an obvious problem 
is that most tumors contain many onco-
genic mutations involved in a number of 
essential signaling pathways,8 and antag-
onizing all of them may provide no 
advantage over traditional chemotherapy 
in terms of adverse effects and toxicity.9 
This is why imatinib, a highly successful, 
rationally designed drug solely targeting 
the BCR-ABL tyrosine kinase in chronic 
myelogenous leukemia (CML), has been 
received with great enthusiasm.10 Tyro-
sine kinase inhibitors (TKIs) have also 
been successfully used in the treatment of 
solid tumors, validating the concept of 
targeting therapy and the importance of 
tyrosine kinase pathways in human 
cancer.11
Tyrosine kinase (TK) signaling path-
ways are effective targets due to their 
role as membrane-localized upstream 
regulators relevant to cancer progres-
sion.12 For instance, receptor tyrosine 
kinases (RTKs) receive extracellular 
stimuli and transduce the signal to mul-
tiple downstream pathways controlling 
many important biological functions 
such as cell proliferation, differentia-
tion, and cell motility.13 Consequently, 
tyrosine phosphorylation controlled by a 
delicate balance between tyrosine 
kinases and phosphatases plays an 
important role in the regulation of many 
hallmarks of cancer, including cell 
growth, angiogenesis, invasion, and 
metastasis.7 Aberrant tyrosine phosphor-
ylation has been reported in many differ-
ent solid tumors and hematological 
malignancies.14,15 Because of the promi-
nent role of TK signaling pathways in 
cancer, a single TKI can have far-reaching 
effects, providing impetus for the pur-
suit of effective targets within tyrosine 
kinase pathways.16 Currently, a major 
problem is that tumors often acquire 
resistance to initial TKI therapy through 
various mechanisms, including the gate-
keeper mutation and activation of other 
TKs, which has led to the development 
of more potent second-generation multi-
target TKIs.17,18 Design of sustainable 
therapeutic strategies and molecular 
diagnosis of TK pathways demands 
comprehensive and versatile analytical 
platforms to decipher phosphotyrosine-
dependent signaling networks in cancer 
cells.
Mass spectrometry (MS) and site-
specific anti-phosphotyrosine antibodies 
are frequently used for the analysis of 
tyrosine phosphorylation in cancer.6,19 
Due to the low abundance of tyrosine 
phosphorylated proteins, enrichment is 
essential prior to the analysis by MS.20 A 
common strategy in which MS is pre-
ceded by the immunoaffinity enrich-
ment of phosphopeptides introduced by 
Rush et al.21 in 2005 has yielded a rich 
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source of information on dysregulated 
kinases and other signaling proteins in 
many types of cancer. One disadvantage 
of this approach is that relatively large 
amounts of cells or tissue are required 
for comprehensive phosphoproteome 
analysis, limiting this approach espe-
cially for clinical applications where 
only a small amount of cancer tissue is 
available. Although the sensitivity of 
MS is greatly improving, typically 100 
to 500 mg of cancer tissues has been 
used in recent phosphoproteomics stud-
ies.5,22,23 The requirement of highly spe-
cialized instrumentation not available in 
every laboratory is another disadvantage 
of MS. Furthermore, it is not always 
obvious whether tyrosine phosphory-
lated peptides identified by MS are 
in fact directly involved in signal trans-
duction or how a pTyr site may affect 
downstream signaling. As an alternative 
to comprehensive MS analysis, anti- 
phosphotyrosine antibodies directed 
against previously defined sites of phos-
phorylation should offer unambiguous 
profiling of phosphotyrosine-dependent 
signaling. At present, a substantial 
number of these site-specific anti- 
phosphotyrosine antibodies are commer-
cially available. However, considering 
the large number of phosphorylation 
sites identified in the proteomes of can-
cer cells, the current panel of antibodies 
would appear to be insufficient. More-
over, a significant number of commer-
cially available antibodies do not offer 
sufficient specificity.24
Concept of SH2 Profiling
Given the limitations of common phos-
phoproteomics strategies, we developed 
SH2 profiling as a complementary 
approach for the characterization of the 
global phosphorylation state.25-27 The key 
components of our analytical platform 
are Src Homology 2 (SH2) domains, nat-
urally occurring protein interaction 
domains that recognize specific phos-
phorylated tyrosine motifs.28 As an inte-
gral part of many important signaling 
proteins, SH2 domains are by far the 
most prevalent phosphotyrosine-binding 
module. There are ~120 different SH2 
domains encoded in the human genome.29 
With a size of approximately 100 amino 
acids, SH2 domains adopt a characteristic 
structure composed of a central antiparal-
lel beta sheet flanked by 2 alpha helices. 
Recognition of phosphotyrosine residues 
is generally mediated by a conserved, 
positively charged arginine residue bur-
ied in the binding pocket of the SH2 
domain. The selectivity of binding to 
tyrosine phosphorylated ligands is deter-
mined by a short stretch of amino acids 
usually spanning 3 to 5 residues C- 
terminal to the phosphotyrosine. Addi-
tional specificity can be conferred by 
N-terminal residues of ligands and a sec-
ondary binding site.30,31 In addition, it has 
recently been shown that SH2 binding 
can be negatively affected by local 
sequence context such that neighboring 
positions influence one another.32 Func-
tionally, binding of the SH2 domains to 
their ligands in the vicinity of the plasma 
membrane couples the molecular switch 
of tyrosine phosphorylation (on) or 
dephosphorylation (off) to downstream 
effectors. Designated as intracellular 
“readers” of the state of tyrosine phos-
phorylation, SH2 domains play a key role 
in the interpretation, processing, and 
transduction of cellular signals.33 This 
unique binding characteristic of SH2 
domains thus confers specificity to signal 
transduction and forms the conceptual 
basis of SH2 profiling (Fig. 1A).
Using a battery of purified SH2 
domains for in vitro binding assays, it is 
possible to quantitatively assess the 
presence of SH2 domain binding sites 
(phosphotyrosine motifs) in analytes 
(e.g., proteins, cell lysates, etc.). In this 
system (SH2 profiling), a positive SH2 
hit suggests that the corresponding SH2 
domain containing protein, if expressed 
in the cell, is involved in tyrosine phos-
phorylation-dependent protein-protein 
interaction as part of a tyrosine kinase 
pathway. Thus, SH2 profiling can pro-
vide functional TK pathway information 
missed in phosphosite cataloguing, mak-
ing SH2 profiling a unique and comple-
mentary approach to conventional 
tyrosine phosphoproteomics (Fig. 1B). 
For example, antibody microarray or 
MS analysis can provide the phosphory-
lation state of tyrosines on a HER2/
ErbB2 receptor in a breast cancer sam-
ple, whereas SH2 profiling can show the 
presence of binding sites for specific 
SH2 domain–containing proteins on the 
same receptor. Noteworthy, SH2 profil-
ing assays are not restricted by previous 
knowledge of phosphorylation sites (i.e., 
unbiased coverage of tyrosine phospho-
proteome), and the sample requirement 
is equivalent to that for phosphoanti-
body-based immunoblotting (i.e., lower 
sample requirement than conventional 
MS). On the other hand, in SH2 profil-
ing, the actual identification of SH2 
ligands requires subsequent antibody or 
MS analysis. Taken together, SH2 pro-
filing provides qualitatively different 
information from conventional pro-
teomics approaches. In view of the 
importance of TK pathways in cancer, 
we hypothesized that SH2 profiling 
could serve as an important diagnostic 
tool that can discern subclasses of 
tumors based on global tyrosine phos-
phorylation state.25
Assay Platforms for SH2 
Profiling
Modular protein interaction domains 
have been widely used as tool in pro-
teomics for various purposes such as 
ligand screening, specificity determina-
tion, and domain-ligand interactome 
analysis.34,35 Similar to antibodies, modu-
lar domains can be used in different 
binding assay platforms defined by 
immobilization and detection methods. 
For example, purified SH2 domain pro-
teins can be arrayed on a solid support 
and incubated with fluorescently labeled 
samples in solution (e.g., forward-phase 
array36), or samples can be arrayed on 
solid phase and incubated with labeled 
SH2 domains in solution (e.g., reverse-
phase array26). Alternatively, interaction 
can be assessed with both samples and 
SH2 domains in solution (e.g., fluores-
cence polarization32). We previously 
observed that a reverse-phase format has 
superior sensitivity over a forward-phase 
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format for analyzing complex whole-cell 
lysates.37 One possible explanation is that 
SH2 domains may be partially inacti-
vated during the immobilization proce-
dures in forward-phase formats. We also 
assume that in reverse phase, binding is 
driven by the relatively high levels of 
SH2 domain protein in solution. Whereas 
in forward phase, the concentration of 
pTyr proteins in lysate solution is 
extremely low, so signal to noise is poor. 
Over the past years, we have developed 
several different analytical platforms for 
SH2 profiling in the reverse-phase format 
(Fig. 1C). All platforms are relatively 
simple, low cost, and amenable to stan-
dard laboratories, although experimental 
setup is a largely manual process in con-
trast with automated high-throughput 
phosphoproteomics systems. Technical 
details have been described in previous 
publications.26,27,38-40
Quantitative Far-Western Analysis
Far-Western blotting is the original plat-
form of SH2 profiling. Whole cellular 
protein extracts are separated by sodium 
dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE), transferred to 
membranes, and subsequently probed 
with a panel of labeled SH2 domain pro-
teins.25,39 Binding of a SH2 domain to 
the membrane-immobilized proteins is 
detected using chemiluminescence. The 
quantitative SH2 binding profiles of dif-
ferent samples are assessed by apparent 
molecular size and intensity of bands. 
An advantage of far-Western over con-
ventional pull-down assays is that inter-
actions between a purified SH2 domain 
and proteins on the membrane are direct, 
whereas proteins detected in a SH2 pull-
down assay may contain indirect bind-
ing partners. Using a cancer cell line 
expressing various tyrosine mutants of 
the PDGF receptor, we demonstrated the 
specificity of SH2 domains, which is 
improved when a labeled SH2 probe is 
mixed with several unlabeled domains 
(competitive binding25). However, we 
do not usually perform competitive 
assays, as various degrees of competi-
tion in binding may quench relevant sig-
nals especially when the concentration 
of phosphoproteins is low.
Although SH2 profiling aims to quan-
titatively analyze many cancer samples 
and SH2 domains in parallel, accurate 
comparison of far-Western blotting 
results from multiple experiments is chal-
lenging due to gel-to-gel and experimen-
tal variations. To overcome the issue, we 
make multiple efforts, including the use 
of a multigel apparatus, normalization by 
internal controls, assay replication, and 
gel band matching with reference blots.40 
For example, pervanadate-treated cell 
lysates and tyrosine phosphatase-treated 
lysates can be used as positive and nega-
tive controls, respectively, to ensure SH2 
probe activity and normalize signal inten-
sity. Reprobing with an anti-pTyr anti-
body also allows for band matching and 
quantification of replicate blots using 
image analysis software. Consequently, 
far-Western blots of multiple samples 
with many SH2 probes can be compared 
and used as the basis for bioinformatics 
analysis.
Rosette Assay
Although far-Western blotting provides a 
rich molecular signature based on SH2 
binding, it is inherently low throughput 
Figure 1. Concept and analytical platforms of SH2 profiling. (A) Diagrammatic view of tyrosine 
kinase signaling state defined by SH2 binding sites. Many extracellular stimuli activate tyrosine 
kinases, resulting in quantitative changes in tyrosine phosphorylated sites on cellular proteins. 
These changes are “read” by specific pTyr-recognizing modules such as SH2 domains, to 
propagate the signal to downstream effectors. These characteristics of SH2 domains form the 
conceptual basis of SH2 profiling. Red circles represent tyrosine phosphorylated sites (P), and 
different SH2 domains are distinguished by color. (B) Different analytical platforms of tyrosine 
phosphoproteomics. Tyrosine phosphorylated peptides are detected by mass spectrometry (MS), 
anti-phosphotyrosine antibodies (pTyr Ab), or SH2 domains (SH2). MS provides information on the 
sequence and type of modification, pTyr Ab provides site-specific phosphorylation status, and SH2 
detects activated, tyrosine phosphorylated SH2 domain binding sites. (C) SH2 profiling platforms. 
In far-Western analysis, protein samples are separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE), and replicate blots are separately probed with horseradish 
peroxidase (HRP)–labeled SH2 domains. In rosette assay, samples are spotted on membrane, and 
the binding assay is carried out in a 96-well plate. HRP-labeled SH2 domain probes are incubated 
with multiple sample spots in a noncompetitive manner (single SH2 per well). In an oligonucleotide-
tagged multiplex (OTM) assay, a mixture of SH2 domains with domain-specific DNA tags are 
incubated with a sample spot allowing for competitive binding (single sample per well). Signal is 
detected either by chemiluminescence (far-Western and rosette) or real-time polymerase chain 
reaction (OTM). Quantified values are used to classify samples, such as different cancer tissues, 
based on SH2 binding preferences (SH2 profiles).
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and requires relatively large amounts of 
sample, therefore precluding comprehen-
sive SH2 profiling (>100 SH2 probes). 
To address this problem, we developed a 
reverse-phase dot-blotting assay platform 
(rosette assay). In the rosette assay, nano-
gram amounts of whole cellular protein 
extract are serially spotted on a mem-
brane in register with the wells of a 
96-well chamber apparatus, allowing 
parallel probing of ~100 SH2 domains in 
a single assay. The number of samples 
analyzed is customizable up to about 100. 
Since the essential reagents for the far-
Western and rosette assays, including 
labeled SH2 probes and detection system, 
are identical, they can be coupled; the 
rosette assay is used for SH2 library 
screening using minimal amounts of 
lysate, and subsequently positive hits are 
confirmed and further analyzed by far-
Western. Based on this strategy, a full 
survey of SH2 interactions using only a 
few hundred micrograms of lysate, with-
out any phospho-enrichment process, is 
feasible.26 The library screening result, 
including positive and negative controls, 
is digitally captured, quantified using 
densitometry, and then further processed 
by bioinformatic analysis.
Oligonucleotide-Tagged Multiplex 
(OTM) Assay
The oligonucleotide-tagged multiplex 
(OTM) assay is a distinctive reverse-
phase assay from rosette. In the rosette 
assay, a single SH2 domain is incubated 
with multiple samples in each well (non-
competitive binding), whereas in OTM, a 
mixture of SH2 domains differentially 
tagged with DNA-oligonucleotides is 
incubated with a single sample. This 
enables multiplex competitive binding 
(Fig. 1C). Biotinylated SH2 domains, 
generated in bacteria using the BirA sys-
tem, are complexed with biotinylated oli-
gonucleotides via a streptavidin bridge. 
Following incubation of the DNA-tagged 
SH2 probes with a sample in a multiwell 
plate, the bound probes are eluted 
and quantified by real-time polymerase 
chain reaction (PCR).27,38 Because it 
incorporates multiplex SH2 binding and 
PCR-based detection, OTM offers 
excellent sensitivity (low femtomole 
amounts of a phosphopeptide) and low 
sample requirement (10 µg of cell extract 
to assess multiple domains). Currently, 
efforts are under way to reduce the com-
plexity of the quantification process 
through absolute quantification of the 
DNA tags by parallel high-throughput 
sequencing.
Technical Considerations
Since SH2 profiling assays rely on 
in vitro purified proteins, activity of 
probes can affect the quality and coverage 
of the system. We and others have 
observed that 30% to 40% of SH2 
domains purified from bacteria are some-
what or completely insoluble, requiring 
refolding or alternative expression sys-
tems.26,36 These domains tend to be inac-
tive when assessed using a phosphatase 
inhibitor–treated positive control, pre-
sumably due to misfolding or degradation 
in the purification step. Various strategies 
to address this issue, including low tem-
perature culture, eukaryotic expression 
systems, and chaperone coexpression, 
have resulted in success for a limited 
number of domains. We also observed 
some instances of substantial improve-
ment using different domain boundaries, 
suggesting a contribution to structural 
stability.
To reduce assay complexity and sam-
ple consumption, it may be possible to 
reduce the number of domains in SH2 
profiling based on their overlapping spec-
ificity. The known 120 SH2 domains can 
be classified into about 30 subfamilies 
according to domain amino acid sequence 
(e.g., Grb2 family: Grb2, Grap, and 
Gads).29 Comprehensive SH2 domain 
studies indicated proteins belonging to a 
family generally have similar binding 
preference,26,30,36 although the possibility 
remains that subtle differences in speci-
ficity observed in vitro can affect ligand 
selection in vivo, such as in the case of 
SHP-1 and SHP-2.41,42
Applications of SH2 Profiling in 
Cancer Research
SH2 profiling has become a versatile 
tool for various levels of cancer studies, 
from the detailed analysis of single pro-
teins to broad screening in translational 
research.25-27,40,43-46 First, a tyrosine site 
on a protein of interest can be readily 
characterized by rosette assay using syn-
thesized peptides. For example, it is well 
established that phosphorylation of 
Y221 of the SH2-SH3 adaptor Crk 
by the Abl kinase results in an inhibitory 
conformation via an intermolecular 
interaction between the Crk SH2 
domain and this phosphorylated residue. 
Recently, another phosphorylation site 
in Crk (pY251) was found in several 
human cancer cell lines.46 To explore the 
biological function of pY251, a rosette 
screen was performed against a SH2 
library. Several SH2 domains, including 
Abl SH2, were found to bind this site, 
and this was confirmed by pull-down 
and surface plasmon resonance (SPR) 
experiments. The Crk pY251 was then 
shown to regulate activation of Abl 
in vitro and in vivo. Interestingly, the 
binding of Abl SH2 and pY251 was rela-
tively weak, consistent with the fact that 
the sequence surrounding Y251 does not 
match the reported Abl SH2 domain 
consensus, suggesting the interaction 
between Crk and Abl is dynamic. 
Similarly, previously uncharacterized 
carboxy-terminal tyrosine phosphoryla-
tion sites in Vav1 were screened by the 
rosette assay, leading to the hypothesis 
that Vav1Y826 and Csk are involved in 
the autoinhibition of NFAT.45 Along 
with identifying candidate binding 
proteins, rosette can provide apparent 
dissociation constants for tyrosine phos-
phorylated peptides by SH2 binding 
curve fitting.43
Second, SH2 profiling has been 
applied to cultured cell samples, provid-
ing the tyrosine phosphorylation signa-
ture of samples based on the presence of 
SH2 binding sites. We showed distinc-
tive SH2 binding patterns in response to 
cell adhesion and growth factor stimula-
tion, as well as in cells expressing differ-
ent oncogenic PTKs.25-27 Notably, SH2 
profiles sometimes can discern a subtle 
change of tyrosine phosphoproteomes. 
For example, ectopic expression of 
oncogenic Src into a mouse fibroblast 
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cell line lacking c-Src, Yes, and Fyn 
kinases induces pre-invadopodia forma-
tion.44 Interestingly, the more invasive 
phenotype capable of matrix degrada-
tion at invadopodia sites requires coex-
pression of wild-type c-Src. In this case, 
the global tyrosine phosphorylation lev-
els of both cell lines are equivalent due 
to the dominant effect of v-Src. How-
ever, a rosette assay detected enhanced 
binding of SH2 domains, including Abl, 
Crk, and Nck, which are known to inter-
act with cortactin, suggesting they play a 
role in the cortactin-mediated invadopo-
dia maturation.44
In addition to focused basic research 
studies, application of SH2 profiling to 
more complex samples such as a set of 
human cancer cell lines is important to 
evaluate assay performance and validate 
it as a diagnostic tool. To this end, we 
examined various lung cancer cell lines 
with different genetic backgrounds such 
as EGFR and KRAS mutations.40 The 
SH2 profiles of cell lines were compared 
using a hierarchical clustering analysis 
for rosette and far-Western data. The 
resulting clusters from both assays were 
overall similar and correlated not only 
with RTK status (EGFR and MET activ-
ity) but also RAS mutation status. For 
example, one cluster was enriched in 
cells with high EGFR and MET activity, 
whereas another cluster contained cells 
with mutant RAS and low EGFR and 
MET activity. Interestingly, far-Western–
based clustering clearly separated 2 RAS 
mutant groups, one of which contained 
an EGF-TKI–sensitive cell line. Since 
KRAS mutation is known a predictor of 
EGFR-TKI resistance with rare excep-
tion (i.e., KRAS mutant and TKI-sensi-
tive),47,48 it will be intriguing to determine 
if SH2 profiling can predict these rare 
cases. Furthermore, assessment of indi-
vidual probes revealed that a group of 
SH2 domains bound more strongly to 
cells with higher sensitivity to EGFR 
inhibitor (erlotinib), suggesting they may 
serve as predictive biomarkers for TKI 
treatment. Taken together, this study 
illustrates the potential of SH2 profiling 
to classify cancer cells from the same 
tumor type independent of oncogene 
mutation status, protein expression, or 
marker status information.
Because tumor cell lines do not nec-
essarily recapitulate the signaling state 
of cancer cells in vivo, we also applied 
SH2 profiling to patient samples. Using 
the quantitative 1-tube OTM assay, we 
analyzed leukemia patient samples (10 
acute myeloid leukemia [AML] and 5 
CML) in comparison with healthy donor 
controls.27 A clustering analysis demon-
strated correlation between the type of 
disease or treatment and SH2 binding: 
One cluster consisted of half of the AML 
samples and presented strong overall 
SH2 binding, the rest of AML and 
untreated CML samples were co- 
clustered, and a cluster of treated CML 
and normal controls with weak signal 
was also clearly separated. By ranking 
the relative levels of SH2 binding for 
each leukemia sample, distinct SH2 
preferences for different diagnostic 
classes became apparent, such as the 
specificity of the GAP SH2 domain 
toward untreated CML. These data sug-
gested that OTM profiling could be used 
to distinguish different types of leuke-
mia. Currently, a rosette screen using a 
larger number of CML and CLL samples 
is under way.
For many of the solid tumors investi-
gated so far, we observed relatively 
weak levels of phosphotyrosine signal in 
all SH2 analytical platforms. As a result, 
some of the subtle but biologically 
important information may be missed if 
these differences are too small to be dis-
tinguished. Since OTM and rosette 
assays provide only a single data point 
for a SH2 domain and a sample, they are 
particularly affected by low signal and 
higher noise levels. To discern more 
subtle differences in the SH2 binding 
pattern, we performed SH2 profiling of 
tumor tissues using quantitative far-
Western blotting (Figs. 2 and 3). In 
accordance to our findings in different 
cancer cell lines, we observed substan-
tial differences in the phosphotyrosine 
profiles between colon cancer and breast 
cancer samples, as well as within each 
tumor type. Based on hierarchical clus-
ter analysis, colon and breast cancer 
samples were grouped in 7 and 4 major 
clusters, respectively. To gain deeper 
insights into the biological relevance of 
the different clusters, we related the 
clusters to the pathological stage of dis-
ease. For colon cancer, no significant 
correlation was observed between the 7 
major clusters and the different stages of 
disease. In addition, as far as data were 
available, no overall correlation was 
found between SH2 profiles and the 
mutational status of the KRAS gene 
(Fig. 2). In contrast, breast cancer sam-
ples from advanced stages of disease 
were significantly overrepresented in 2 
of the 4 major clusters (Fig. 3, clusters c 
and d, respectively; P < 0.001).
In an attempt to assign the differences 
in phosphoactivity depicted by SH2 pro-
filing to tyrosine kinase activity, we 
determined the protein expression levels 
of MET and members of the ErbB-family 
frequently altered or overexpressed in 
colon and breast cancer, respectively. 
Strikingly, a high level of MET expres-
sion was significantly correlated with 3 
closely related colon cancer clusters (Fig. 
2, clusters d, e, and f, respectively; P < 
0.001). In breast cancer, increased levels 
of ErbB2 and ErbB3 expression were sig-
nificantly overrepresented in the 2 clus-
ters (c and d, respectively; P < 0.001), 
concurrently correlating with advanced 
stages of disease. Taken together, our 
data demonstrate that SH2 profiling of 
clinical samples may provide a rich 
source of important and potentially pre-
dictive information about cancer cell sig-
naling and patient outcomes.
Challenges
Our collective efforts in the past decade 
have validated the original concept of 
SH2 profiling: A set of SH2 domains can 
serve as a means to profile the global tyro-
sine phosphorylation state. We showed 
SH2 profiling is a powerful tool to predict 
biological partners for a specific tyrosine 
motif on a protein and to classify cancer 
cells. The 3 analytical platforms are 
358 Genes & Cancer / vol 3 no 5-6 (2012)M Monographs
versatile in that rosette assay serves as a 
rapid SH2 library screening tool, quantita-
tive far-Western analysis provides a func-
tional signature of the tyrosine 
phosphoproteome, and OTM offers a sen-
sitive 1-tube competitive binding assay. 
We recognize, however, technical hurdles 
and challenges exist for the application of 
SH2 profiling to translational cancer 
research. Clinical specimens are usually 
limited in quantity and availability. Con-
sidering the future diagnostic application, 
it is ideal that all analyses be carried out 
with the amount of tissue provided by a 
needle biopsy (~10 mg tissue).49 For cul-
tured cell samples, SH2 profiling is sensi-
tive enough without phosphoprotein 
enrichment, thereby requiring a smaller 
amount of sample than for MS-based 
phosphoproteomics. In the case of solid 
tumor specimens, however, we some-
times observe a significantly lower signal 
level than with cultured cells, increasing 
sample requirement. Low signal-to-noise 
levels affect data quality, particularly for 
the rosette and OTM screening platforms. 
In these systems, one SH2 probe gives 
only one data value as the binding assay is 
performed within a sample dot. To detect 
subtle differences in SH2 binding between 
tumor samples, sufficient signal intensity 
is necessary. As a result, quantitative 
phosphotyrosine profiles may not fully be 
captured by the OTM and rosette assay. 
On the other hand, quantitative far-West-
ern, which requires 15 to 50 µg per SH2 
domain probe, can reveal distinct SH2 
binding patterns, and thus tumor-specific 
clusters are visible (Figs. 2 and 3). This 
dilemma between sample requirement 
and data quality is currently a hurdle for 
implementation of SH2 profiling to large-
scale tumor analysis. Nevertheless, the 
observation that 5 selected SH2 domains 
were sufficient to provide distinct clusters 
relevant to breast cancer stages (Fig. 3) 
suggests that the use of rosette/OTM to 
exclude domains with low signal prior to 
far-Western could minimize sample 
consumption.
Low phosphotyrosine signals can in 
part be attributed to heterogeneity and 
impurity of cancer tissue specimens, 
which contain various amounts of normal 
cells and connective tissues. This is con-
sistent with the fact that purified hemato-
poietic cells usually show better quality 
data, and disease-relevant SH2 profiles 
have been obtained using the OTM 
assay.27 In addition, in a preliminary 
rosette screening, we observed that 
HER2/ErbB2-positive tumors were co-
clustered by their strong binding to 
known SH2 domains downstream of 
HER2/ErbB2. Thus, we assume OTM/
rosette SH2 platforms should be capable 
of differentiating tumors containing a 
higher percentage of cancer cells and/or 
driven by TK oncogenes. We note, how-
ever, that some normal cells such as 
immune cells associated with inflamma-
tory tumors can contribute to the malig-
nant phenotype of cancer.7
Perspectives
Toward personalized molecular diagnosis 
using SH2 profiling, we are attempting to 
Figure 2. SH2 profiling of colon cancer. Tumors samples (n = 57) were snap frozen immediately 
after surgical removal and whole cellular extracts were prepared as previously described.25 Far-
Western blot analysis was performed with 20 µg of lysate per sample. Lysates were separated 
on 4% to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gradient 
gels, transferred to PDVF membranes, and probed with biotinylated SH2 domains. Streptavidin–
horseradish peroxidase (HRP) conjugate was used for detection. Images were scanned and 
analyzed by the ImageJ software (National Institutes of Health, Bethesda, MD), and digitalized 
profiles were segmented into bins as previously described.40 Subsequently, correlative, 
unsupervised hierarchical cluster analysis was performed using the MeV software (version 4.6; 
MeV, Boston, MA). The 7 major clusters (a-f) identified by cluster analysis are shaded in gray. Levels 
of MET expression, determined by Western blot analysis, were categorized as moderate or strong; 
lack of MET expression was categorized as absent. The genomic status of codons 12 and 13, 
respectively, of the human Kras gene was determined by restriction fragment length polymorphism 
(RFLP) analysis as previously described.40 Pathological staging is given in accordance with the 
2010 American Joint Committee on Cancer classification.
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assign different SH2-based clusters to 
clinically relevant parameters associated 
with cancer development, progression, 
and effective therapeutic intervention.50 
As suggested by our data on lung cancer 
cell lines and native breast cancer sam-
ples, SH2 profiling may be of particular 
value for improved classification of 
tumors and stratification of patients in 
combination with established clinical 
and pathological parameters. Establish-
ing this would require well-controlled 
retrospective or prospective studies of 
cancer patients treated with different drug 
combinations, including tyrosine kinase 
inhibitors, to demonstrate that therapeutic 
benefits and improvements in the clinical 
course of disease can be predicted by 
SH2 profiling. However, it may be naive 
to assume phosphotyrosine profiles 
detected by a single modular domain 
family can be an independent prognostic 
marker for human cancer, a complex 
genetic disease. To fully decipher aber-
rant signaling in cancer in detail with the 
aim of identifying specific therapeutic 
targets, additional information beyond 
the mere SH2 profile may be needed. 
We assume TK signaling status as a 
whole may predict patient outcome, par-
ticularly in a subset of tumors where TK 
signaling drives oncogenesis. How can 
this comprehensive view of TK signaling 
status be captured? As tyrosine kinases 
and phosphatase are the key players con-
trolling the cellular state of phosphoryla-
tion, comprehensive profiling of kinase/
phosphatase expression may be one 
promising approach to guide the interpre-
tation and classification of SH2 profiles, 
as exemplified above for the kinases 
MET and ErbB in colon and breast can-
cer. For instance, expression data of par-
ticular kinases, phosphatases, and SH2/
PTB proteins will be useful in specifying 
the pTyr-dependent protein interactions 
that actually occur in cells. SH2 profiling 
(using purified SH2 domains) detects the 
presence of binding sites for SH2 
domain–containing proteins regardless of 
their expression in cell, whereas gene or 
protein expression indicates the protein is 
actually available to mediate signaling. 
Expression data can also help in the effi-
cient design of SH2 profiling assays 
through the exclusion of unexpressed 
SH2 proteins.
Knowledge of the genomic status and 
activity of kinases and phosphatases will 
also without doubt provide important 
information for the classification of SH2 
profiles. Correlations between SH2 pro-
files and somatic mutation in kinase/
phosphatase genes are informative to 
specify activated TK signaling networks. 
Furthermore, combining SH2 profiling 
with other phosphoproteomics tools may 
also turn out to be a powerful combinato-
rial strategy. Detailed characterization of 
tyrosine phosphorylated proteins by MS 
after pull-down of phosphoproteins with 
informative SH2 domains should have 
great potential, enabling the identifica-
tion of executors and substrates of tyro-
sine phosphorylation, which may serve as 
potential targets for the development of 
rational therapies.
Conclusion
As demonstrated for many different 
tumor cell lines and native tumor sam-
ples, SH2 profiling is a powerful tech-
nique for deciphering and classifying 
aberrant phosphotyrosine-dependent sig- 
naling in cancer. Given its sensitivity and 
Figure 3. SH2 profiling of native breast cancer samples. Profiling of tumor samples (n = 34) and 
processing of profiles were performed as described in Fig. 2. The 4 major clusters (a-d) determined 
by correlative, unsupervised clustering are shaded in gray. Normal breast tissue (N) served as a 
control. Protein expression levels of ErbB2, ErbB3, and ErbB4 were determined by Western blot 
analysis.
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relatively small sample requirement, SH2 
profiling may be of extraordinary value 
for the analysis of tumor tissues and mon-
itoring of tumors during therapy where 
only limited amounts of cancer cells are 
present. It may also provide “geographi-
cal” profiles of the tyrosine phosphoryla-
tion state in different areas of the tumor, 
addressing the important issue of tumor 
heterogeneity and diversity of signaling. 
SH2 profiling, in combination with other 
phosphoproteomics tools and informat-
ics, is evolving as a simple, robust, and 
highly sensitive technique with both 
research and clinical applications.
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